SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children. This landmark decision is driving widespread community discussion about its de-risking impact, significant revenue potential, and possible short squeeze, with many speculating on substantial price targets and a potential buyout by a larger pharmaceutical entity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its high-speed, compliance-first Layer 1 infrastructure, which boasts impressive transaction throughput. The community is actively discussing its potential as a "financial plumbing" solution for institutions, especially with its integration of a fiat anchor from Bridge (a Stripe company) now operational. Many view KTA as an undervalued asset for cross-chain settlement and regulated financial flows, positioning it as a compelling complementary play to established crypto and tech giants.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after federal regulators approved an emergency permit and granted interstate status for its Santa Ynez Pipeline System, shifting regulatory authority from California to federal oversight. This is widely seen as a game-changing event that could enable the company to finally move stored oil and potentially trigger a short squeeze. However, some investors remain cautious about possible state-level legal challenges or the potential for future equity offerings.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

YEE Crypto is experiencing a surge in attention, driven by a fiercely loyal community actively buying dips and declaring it a generational opportunity within the Ethereum ecosystem. The conversation centers on an unfolding 'prophecy,' strong bullish momentum, and comparisons to legendary meme coins, positioning YEE as a potential catalyst for significant growth.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amid widespread community accusations of being a "scam" or "rugpull," with many investors expressing deep frustration over its recent performance. Sentiment is heavily bearish, with calls to sell and shift assets to other cryptocurrencies like XRP, though a smaller group sees current price levels as an opportune time for accumulation ahead of a potential rebound.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently seeing a surge in conversation and trading volume following reports of significant insider stock purchases, notably by Apple CEO and Nike board member Tim Cook. This move has ignited fervent debate among the community, with many interpreting it as a strong vote of confidence and a potential turning point for the struggling brand, while skeptics question its fundamental impact amidst ongoing performance concerns.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to promising preliminary Phase 3 open-label data indicating a significant reduction in breast cancer recurrence rates. The community is actively discussing the very high cost-to-borrow rates and a low share float, fueling strong short-squeeze speculation. This is compounded by significant insider buying from the CEO, leading to widespread anticipation of a major partnership or acquisition within the biotech sector.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock after securing FDA approval for its oral Wegovy pill, marking a significant milestone as the first GLP-1 oral therapy for weight management. The community is buzzing with excitement over the convenience of a pill versus injections, anticipating a massive expansion of the obesity market and a competitive edge against rivals. Investors are looking for a substantial re-rating of the stock, believing this approval signals a new era of growth and market leadership.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by positive regulatory developments, strategic divestitures, and key partnerships in wealth management and digital payments. This rally has sparked extensive community discussion, with many celebrating its strong performance and ongoing transformation plan, while others express caution due to its rapid ascent and overbought technical indicators. The positive sentiment is reinforced by strong earnings and analyst upgrades, positioning it as a notable performer within the broader financial sector.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is seeing heightened conversation following a recent US$20 million public offering aimed at funding its demonstration-scale plant. Enthusiastic investors highlight the company's graduation from Shell's GameChanger program and new partnerships as strong validation for its unique recycling technology, while skeptics warn of a "pump and dump" lacking revenue and view the valuation as unsustainable.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Instacart acquired Eversight in 2022 whose AI-powered software allows retailers to test customized pricing and promotions directly with their individual customers.</li><li>The company said on Monday that while retail partners will continue to set their own prices on Instacart and they may choose to vary the price of items on a store-by-store basis, Instacart will not support any item price testing services.&nbsp;</li><li>The company also said that the pricing tests were not dynamic pricing or surveillance pricing and added that they were never based on supply or demand, personal data, demographics, or individual shopping behavior.</li></ul> Instacart (<a href="https://stocktwits.com/symbol/CART">CART</a>) said on Monday that retailers will no longer be able to use artificial intelligence-driven pricing tests on its grocery delivery platform after it drew flak from customers and the federal trade commission.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.instacart.com/company/updates/ending-item-price-tests-on-instacart">said</a> that retailers will no longer be able to use Eversight technology to run item price tests on Instacart. Instacart acquired Eversight in 2022 whose AI-powered software allows retailers to test customized pricing and promotions directly with their individual customers. According to Instacart, several retailers rely on Eversight to optimize pricing including The Giant Company, Schnucks, and Kroger. Grocers who used Eversight have recorded revenue growth of 1-3%, according to the company.However, this caused shoppers to pay different prices for identical items from the same store.“We understand that the tests we ran with a small number of retail partners that resulted in different prices for the same item at the same store missed the mark for some customers. At a time when families are working exceptionally hard to stretch every grocery dollar, those tests raised concerns, leaving some people questioning the prices they see on Instacart. That’s not okay,” Instacart said. “Now, if two families are shopping for the same items, at the same time, from the same store location on Instacart, they see the same prices — period.”<h2 class="st-heading-2">New Pricing Rules</h2>Instacart said on Monday that while retail partners will continue to set their own prices on Instacart and they may choose to vary the price of items on a store-by-store basis, Instacart will not support any item price testing services.“We’ll continue working closely with partners to remove markups where possible and better align their online prices with their in-store prices,” the company said.The company also said that the pricing tests were not dynamic pricing or surveillance pricing and added that they were never based on supply or demand, personal data, demographics, or individual shopping behavior.<h2 class="st-heading-2">Eversight Draws Flak</h2>Earlier this month, Consumer Reports <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.consumerreports.org/money/questionable-business-practices/instacart-ai-pricing-experiment-inflating-grocery-bills-a1142182490/#:~:text=Many%20U.S.%20shoppers%20who%20order,Sprouts%20Farmers%20Market%2C%20and%20Target.">noted</a> that the AI-enabled pricing experiments on Instacart caused price differences of as much as 23% for identical products from one customer to the next. The report also said that Instacart’s algorithmic pricing experiments were found to be occurring through the platform at several of the nation’s biggest grocery retailers, including Albertsons, Costco, Kroger, Safeway, Sprouts Farmers Market, and Target.Following the investigation by Consumer Reports, Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/ftc-investigating-instacarts-ai-pricing-tool-source-says-2025-12-17/">reported</a> that the U.S. Federal Trade Commission is probing Instacart and seeking information about its Eversight pricing tool. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>CART shares traded 2% lower at the time of writing. On Stocktwits, retail sentiment around CART stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CART stock has risen 8% this year and by about 6.5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-interim-trial-results-in-chemotherapy-induced-pain-fail-to-boost-investor-confidence/cLeF8WPREMu">DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Instacart Pulls Plug On AI-Driven Grocery Pricing Tests After Shopper Backlash And Regulatory Scrutiny

The company said that retailers will no longer be able to use Eversight technology to run item price tests on Instacart.

Equity

The company said that retailers will no longer be able to use Eversight technology to run item price tests on Instacart.


<ul class="summary-bullets"><li>Deal signals continued demand for space and defense technology as firms look to beef up their offerings.</li><li>CACI said it expects to realize a tax benefit with a present value of $225 million.</li><li>Donald Trump recently signed a record $901 billion defense bill for the U.S.</li></ul>CACI International (CACI) on Monday announced it has agreed to acquire ARKA Group in an all-cash deal valued at $2.6 billion, from funds managed by Blackstone Tactical Opportunities, to expand its offerings in the national security and space sectors.&nbsp;The transaction is expected to close in the third quarter of fiscal year 2026, the statement said.&nbsp;The all-cash deal signals continued demand for space and defense technology as firms look to beef up their offerings in this sector amid ongoing global conflicts and rising geopolitical tensions in Asia and Europe, prompting nations to increase defense spending.The deal will help CACI add ARKA’s space-based sensor systems and ground-based software processing products to its portfolio.CACI said it expects to realize a tax benefit with a present value of $225 million and noted that the ARKA transaction is expected to close in the third quarter of fiscal year 2026.“The acquisition of ARKA positions CACI to capture significant future opportunities in the space domain across the Intelligence Community, U.S. Space Force, and other Department of War customers,” said John Mengucci, CACI President and Chief Executive Officer. &nbsp;<h2 class="st-heading-2">Demand For Defense Tech</h2>The demand for defense and intelligence contracts has been on the rise as countries look to beef up their defense capabilities amid rising global tensions among several nations.The U.S. Congress recently passed a record $901 billion defense bill, later signed by Donald Trump, that included a pay raise for troops and security aid to Ukraine. It also included funding for Trump’s “golden dome” missile defense system.Global military spending is projected to hit $2.56 trillion in 2025, more than $420 billion higher than the level before the outbreak of the war in Ukraine, according to a<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.janes.com/osint-insights/open-source-intelligence-webinars/2025-defence-budgets-annual-report"> report</a> from Janes, an open-source data provider for defense intelligence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/RKLB">CACI International shares</a> were up nearly 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.&nbsp;<figure class="image"><img style="aspect-ratio:793/93;" src="https://news.stocktwits-cdn.com/caci_PNG_cd6d6bca25.webp" alt="Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory." width="793" height="93"></figure>CACI shares have gained over 35% this year.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/caci-international-to-acquire-arka-from-blackstone-funds-in-2-6-b-cash-deal/cLeF0pSREM4">directly on Stocktwits</a>.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-h200-ai-chips-china-exports-february-2026/cLeFLp7REMd">Nvidia May Resume H200 AI Chip Exports To China In February, Days After Trump Administration Begins Policy Review: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 The U.S. headquarters of CACI International Inc. is seen May 12, 2004 in Arlington, Virginia. (Photo by Mark Wilson/Getty Images)

What’s Behind CACI’s $2.6B Acquisition of ARKA?

ARKA Group offers space-based sensor technology and optical technology that will enable CACI to expand its offerings

ARKA Group offers space-based sensor technology and optical technology that will enable CACI to expand its offerings. 


<ul class="summary-bullets"><li>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule.&nbsp;</li><li>Wall Street analysts dismissed the media report hinting at approval delays and termed the share drop as overblown.&nbsp;</li><li>Disc Medicine is hopeful for an approval of the drug by the end of January 2026.</li></ul>Shares of Disc Medicine (<a href="https://stocktwits.com/symbol/IRON">IRON</a>) plunged 12% on Friday after a report flagged concerns pertaining to the U.S. Food and Drug Administration’s speedy approval of the company’s blood disorder drug Bitopertin.Disk Medicine’s Biopertin for the treatment of Erythropoietic Protoporphyria (EPP) is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program. The Commissioner's National Priority Voucher program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.However, Stat News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/12/19/fda-voucher-program-political-interference/">reported</a> on Friday, citing government officials, that high-level FDA officials have been involved in every part of the new program involving the vouchers. The political pressure is creating “uncomfortable situations” for career scientists at the FDA, the report said.The report dragged down investor sentiment and hopes for an expedited approval of Bitopertin as the report also noted that FDA senior official Vinay Prasad raised doubts about the drug’s effectiveness.<h2 class="st-heading-2">Wall Street Dismisses Concerns</h2>Jefferies analyst Roger Song, however, termed the share drop a “stock overreaction”. Song said that while the priority voucher program's timeline may be under pressure with increasing demand, the firm remains confident on Bitopertin's approval in EPP under the program, based on robust efficacy and safety data and to-date review experience.TD Cowen also maintained its ‘Buy’ rating on the shares and said the firm believes skepticism on the program’s path is overblown. Disc's management remains confident, it noted, and added that the firm's confidence in accelerated approval remains high.BMO Capital said that it had discussions with Disc Medicine’s management which highlighted a lack of interactions with senior official Prasad but robust active dialogue with the FDA. While Prasad may have speculated efficacy concerns related to Bitopertin, these have not been communicated to Disc, and no clear concerning questions around efficacy have been raised, BMO added. Some procedural questions have been asked by FDA in trying to understand the Bitopertin data package and how it may translate to clinical benefit, it said. The firm has an ‘Outperform’ rating on the shares with a price target of $120.<h2 class="st-heading-2">Management Takeaway</h2>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule and expressed hopes for potential launch by the end of January 2026, consistent with the 1-2 month timeline for drugs which receive the priority voucher.“Our commercialization efforts have been accelerated significantly and we are well on our way to launch readiness,” the company said.The company submitted its application for approval in patients aged 12 years and older with EPP on September 29. Erythropoietic Protoporphyria (EPP) is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight (phototoxicity), leading to immediate, painful skin reactions like burning, tingling, redness, and swelling, due to the buildup of protoporphyrin in red blood cells from an enzyme deficiency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.IRON stock has gained about 26% this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-intel-shares-jump-after-us-antitrust-agencies-clear-5-billion-deal/cLe0d1gREtc">Nvidia, Intel Shares Jump After US Antitrust Agencies Clear $5B Deal That Deepens Their Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’

Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 

<ul class="summary-bullets"><li>The Idaho office of the U.S. Department of Energy has granted the Preliminary Documented Safety Analysis for the firm’s Aurora Fuel Fabrication Facility.</li><li>The next step would be to obtain a Documented Safety Analysis (DSA), the third document that would provide an update on the facility's final design and construction.&nbsp;</li><li>Oklo is on the list of companies selected for the DOE’s nuclear pilot programs.&nbsp;</li></ul>Oklo Inc. (OKLO) announced on Tuesday that the U.S. Department of Energy’s (DOE) Idaho office has given an initial safety approval for its Aurora Fuel Fabrication Facility, effectively granting permission to start facility assembly.The DOE’s Idaho Operations Office has granted the nuclear technology company the Preliminary Documented Safety Analysis (PDSA) for Aurora, the first facility approved under the DOE’s Fuel Line Pilot Program, the company said.The PDSA is the second out of three safety documents for the facility’s approval. Oklo said that the next step would be a Documented Safety Analysis (DSA), an update about the final design and construction of the facility.<h2 class="st-heading-2">DOE Nuclear Pilot Programs</h2>Earlier this year, the DOE launched new pilot programs to hasten the development of advanced nuclear reactors and domestic fuel following Executive Orders from President Donald Trump to streamline national laboratory processes for reactor testing.As part of this, the DOE issued a Request for Application (RFA) seeking U.S. reactor companies to construct and operate test reactors outside of the national laboratories with DOE authorization. Oklo is among the companies selected for the program. The Aurora facility will combine fuel production and power delivery to enable the commercial deployment of nuclear energy.“By advancing modern fuel fabrication and recycling, we’re addressing fuel-supply constraints, improving the economics of our powerhouses, and opening new long-term revenue streams for the business,” Oklo’s co-founder and CEO, Jacob DeWitte, said. “We’re moving swiftly toward full deployment of this fuel facility where we will repurpose fuel from the legacy Experimental Breeder Reactor-II (EBR-II) for use in Oklo’s Aurora-INL.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/OKLO">OKLO</a> remained ‘bearish’ over a week, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1298/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_16_at_5_32_35_PM_png_589c7406cd.webp" alt="On Stocktwits, the retail sentiment around OKLO remained ‘bearish’ over a week, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing." width="1298" height="148"></figure>Shares of OKLO were down 0.28% in Tuesday’s pre-market at the time of writing and have surged over 345% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, a person holds a smartphone displaying the logo of Oklo Inc.

Oklo Gets Initial Safety Approval From DOE For Aurora Facility To Begin Assembly 

Aurora is the first facility approved under the DOE’s Fuel Line Pilot Program, the company announced on Tuesday. 

<ul class="summary-bullets"><li>The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024.</li></ul>Shares of Anavex Life Sciences Corp. (AVXL) fell 3% after hours on Friday after the company said that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a negative opinion on its application seeking approval for the drug Blarcamesine in treating Alzheimer’s disease.In November, Anavex <a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E">said </a>it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation in a session held behind closed doors on Nov. 11. The company was awaiting a formal opinion from the committee.<h2 class="st-heading-2">Negative Opinion ‘As Expected’</h2>Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early">said</a> on Friday that the CHMP has indeed adopted a negative opinion “as expected.” CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination, independent from the first opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Besides Alzheimer’s, Anavex is also studying Blarcamesine in treating Parkinson's disease dementia and Rett syndrome.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.A Stocktwits user opined that this is the best time for big pharma players “to throw bone for this company” provided the low share price and “promising assets.”&nbsp;<stembedurl>https://stocktwits.com/lookupdownside/message/639061239</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 63% this year and by 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-denies-data-center-delay-report-after-shares-slide-on-openai-build-out-concerns/cLICt16RE8O">Oracle Denies Data Center Delay Report After Shares Slide On OpenAI Build-Out Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential

Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.”

<ul class="summary-bullets"><li>Sarepta is set to exchange 1.25% convertible senior notes due 2027 for new 4.875% convertible senior notes due 2030, alongside about $31.6 million in cash.</li><li>The transaction is slated to be completed around Dec. 18, 2025.&nbsp;</li><li>The deal would involve the purchase of approximately 691,000 SRPT common stock, the company said.&nbsp;</li></ul>Sarepta Therapeutics Inc. (SRPT) shares tumbled more than 6% on Thursday after the company announced a debt refinancing plan totaling about $291 million.&nbsp;The drug manufacturer said that, as per the privately negotiated agreements, it would exchange $291.4 million of 1.25% convertible senior notes due 2027 for the same amount of new 4.875% convertible senior notes due 2030 alongside about $31.6 million in cash.The deal is expected to close around Dec. 18, 2025.&nbsp;<h2 class="st-heading-2">Deal Details</h2>After the debt refinancing, the aggregate principal amount of SRPT’s 4.875% convertible senior notes due 2030 will be approximately $893.4 million. This would result in $158.6 million in aggregate principal amount of the existing notes to remain outstanding under the previous terms, the company said.&nbsp;The transaction would also entail the sale by the private parties of approximately 691,000 shares of the company’s common stock,&nbsp;which could affect the market price of the company’s shares and notes, the firm noted. Since the deal is private, none of the new notes and shares issuable upon conversion are registered for public sale.Most recently,&nbsp;<a href="https://stocktwits.com/symbol/SRPT/">SRPT</a> issued an equity grant of about $12 million to Douglas S. Ingram, its chief executive officer. In November, the company also received FDA approval to begin a new study to test the impact of immunosuppressant sirolimus on liver injury in non-ambulatory Duchenne patients.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, SRPT was among the top 10 trending stocks on Thursday morning. The retail sentiment around SRPT jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1290/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_8_56_01_PM_png_5f8dc3f44e.webp" alt="SRPT stock sentiment and message volume." width="1290" height="150"></figure>Shares of SRPT are down over 83% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Is SRPT Stock Falling Today?

Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million. 

In this photo illustration, a person holds a smartphone displaying the logo of Rocket Lab USA Inc.

Rocket Lab Is Finally Having Its SpaceX Moment — Yet One Grounded Project Could Make Or Break This Year’s Fantastic Surge

When compared to the first quarter of 2021, Rocket Lab’s recent quarter reported a revenue surge of 750%, making the third quarter of this year its best one ever.

<ul class="summary-bullets"><li>SAIC's third-quarter adjusted earnings per share of $2.58 beat analyst estimates of $2.06.&nbsp;</li><li>Revenue for the quarter came in line with estimates at $1.87 billion.&nbsp;</li><li>The company also raised its adjusted diluted EPS guidance to $9.80 to $10.00, up from $9.40 to $9.60 earlier.</li></ul>Science Applications International Corporation (SAIC) shares traded over 16% higher on Thursday following upbeat third-quarter results and improved guidance.The defense and technology company posted adjusted earnings per share (EPS) of $2.58, far beating the analyst consensus of $2.06, according to Fiscal.ai data. Revenue for the quarter was $1.87 billion, in line with estimates, although 6% lower than the same period last year.SAIC also raised its adjusted earnings before interest, tax, depreciation and amortization (EBITDA) guidance to about $695 million, up from between $680 million and $690 million previously. It is also projecting adjusted diluted EPS of $9.80 to $10.00, up from $9.40 to $9.60 reported before."Our third quarter results reflect a 5.6% revenue contraction, slightly ahead of our guidance when adjusting for the approximate 1% headwind from the government shutdown, and strong margins due to continued sound program execution,” said Jim Reagan, SAIC Interim Chief Executive Officer, in the statement.<h2 class="st-heading-2">Against The Odds</h2>SAIC’s stellar performance comes despite the recent government shutdown, which has affected several federal contractors this quarter. About 98% of the company’s total revenues come from government contracts or subcontracts, the company had said earlier in a filing.Its operating income as a percentage of revenues decreased in the quarter compared with the same period last year, which it attributed to executive transition costs related to a contract termination.SAIC also acquired SilverEdge Government Solutions, a provider of technology solutions and products, last month. The company said that the deal enhanced its strategy to provide mission-focused, IP-based solutions and commercial products to its customers.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment surrounding the stock shifted to ‘extremely bullish’ from ‘neutral’ while message volume jumped to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1276/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_9_01_20_PM_png_3582235eb8.webp" alt="Stocktwits retail sentiment shifted to ‘extremely bullish’ from ‘neutral’ and message volume jumped to ‘extremely high’." width="1276" height="158"></figure> SAIC shares have lost over 9% this year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/wedbush-backs-snowflake-after-q3-print-suggests-buying-the-dip/cLILyrXRESt">Wedbush Backs Snowflake After Q3 Print, Suggests Buying The Dip</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

AeroVironment exhibited during the Defense Expo Korea 2022, held at KINTEX (Korea International Exhibition and Convention Center) on September 21, 2022 in Goyang city, Gyeonggi, South Korea.  (Photo by Chris Jung/NurPhoto via Getty Images)

SAIC Stock Surges Post Upbeat Q3 Earnings, Improved Guidance

The defense and tech company’s adjusted earnings per share of $2.58 beat analyst estimates by over $0.50. 

<ul class="summary-bullets"><li>Redemplo was approved by the FDA earlier this month, marking a milestone for Arrowhead as it becomes a commercial-stage company.</li><li>The company said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis.</li><li>Arrowhead reported revenue of $829.4 million in fiscal year 2025, compared to $3.55 million in FY24.</li></ul> Morgan Stanley on Wednesday raised its price target on Arrowhead Pharmaceuticals (ARWR) to $48 from $45 while keeping an ‘Equal Weight’ rating on the shares.Shares of the company traded 22% higher at the time of writing on Wednesday morning.According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)." Severe hypertriglyceridemia refers to a medical condition where there are dangerously high levels of triglycerides in the blood.<h2 class="st-heading-2">Significance Of Redemplo Approval</h2>Redemplo is Arrowhead’s first FDA-approved medicine. Its approval earlier this month as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome marked a milestone for Arrowhead as it evolves into a commercial-stage pharmaceutical company.Familial chylomicronemia syndrome (FCS) is a rare, genetic disorder where the body cannot properly break down fat, leading to extremely high levels of triglycerides in the blood. Arrowhead estimates that about 6,500 people in the U.S. are living with FCS.“Arrowhead is truly just getting started, and we are well-positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years,” Arrowhead CEO Christopher Anzalone said on Tuesday.The company also said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis due to high triglyceride levels.<h2 class="st-heading-2">FY25 Earnings</h2>Arrowhead <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results/">reported</a> revenue of $829.4 million in fiscal 2025 (FY25), compared to $3.6 million in FY24, and above an analyst estimate of $757.44 million.Net loss per share came in at $0.01, down from the loss of $5 reported in FY24, and lower than an analyst estimate of a loss of $0.03 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ARWR jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume remained at 'high' levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than tripled this year and risen by about 172% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-posts-unexpected-loss-in-q3-as-ev-sales-drop/cL53uOfREWq">Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest EAOR News

EAORiShares ESG Aware 60/40 Balanced Allocation ETF